Meloxicam/rizatriptan
| Combination of | |
|---|---|
| Meloxicam | Nonsteroidal anti-inflammatory drug |
| Rizatriptan | serotonin (5-HT) 1B/1D receptor agonist (triptan) |
| Clinical data | |
| Trade names | Symbravo |
| License data | |
By mouth | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Meloxicam/rizatriptan, sold under the brand name Symbravo, is a
by mouth.[1]
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]
Medical uses
Meloxicam/rizatriptan is
Society and culture
Legal status
Meloxicam/rizatriptan was approved for medical use in the United States in January 2025.[2]
References
- ^ a b c d e "SYMBRAVO (meloxicam and rizatriptan) tablets, for oral use" (PDF). Axsome Therapeutics, Inc. U.S. Food and Drug Administration.
- ^ a b "Axsome Therapeutics Announces FDA Approval of Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults" (Press release). Axsome Therapeutics. 30 January 2025. Retrieved 7 February 2025 – via GlobeNewswire.
- PMID 36031682.
External links
- Clinical trial number NCT03896009 for "Maximizing Outcomes in Treating Acute Migraine (MOMENTUM)" at ClinicalTrials.gov
- Clinical trial number NCT04163185 for "Initiating Early Control of Migraine Pain and Associated Symptoms (INTERCEPT)" at ClinicalTrials.gov
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
profens ) |
|
| n-arylanthranilic acids ( fenamates ) | |
COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
